Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Meiragtx Holdings ( (MGTX) ) has shared an update.
On April 15, 2026, MeiraGTx reacquired from Janssen all rights and related intellectual property to botaretigene sparoparvovec (bota-vec), an AAV-RPGR gene therapy for X-linked retinitis pigmentosa, for $25 million upfront plus potential milestones and royalties, while Johnson & Johnson’s investment arm agreed to a 12‑month lock-up on its MeiraGTx stake. The deal follows termination of a prior 2023 asset purchase structure, consolidates ownership of the RPGR program, and positions MeiraGTx to seek global approvals and commercialize bota-vec itself, supported by Phase 3 LUMEOS data showing strong secondary endpoint efficacy, manageable safety, and an estimated XLRP market of more than 20,000 patients in the U.S. and EU.
The company also detailed an April 2, 2026 amendment to its collaboration with Hologen, under which Hologen issued MeiraGTx shares and restructured funding mechanics for a previously agreed $200 million upfront payment tied to neuro and manufacturing joint ventures. These changes are intended to finalize Hologen’s equity stakes in MeiraGTx’s neuro AI and manufacturing entities and secure the remaining upfront funding, bolstering MeiraGTx’s capital base as it prepares for potential launches of bota-vec and its AAV-hAQP1 therapy for radiation-induced xerostomia from 2027 onward.
The most recent analyst rating on (MGTX) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Meiragtx Holdings stock, see the MGTX Stock Forecast page.
Spark’s Take on MGTX Stock
According to Spark, TipRanks’ AI Analyst, MGTX is a Neutral.
The score is held back primarily by weak financial fundamentals—large ongoing losses, continued cash burn, and a deteriorated capital structure with negative equity—despite strong recent revenue/gross margin improvement. Technicals are constructive with the stock in an uptrend, and corporate events add support via regulatory and partnership/financing developments, but valuation remains challenging given negative earnings.
To see Spark’s full report on MGTX stock, click here.
More about Meiragtx Holdings
MeiraGTx Holdings plc is a vertically integrated, clinical-stage genetic medicines company focused on adeno-associated virus (AAV) gene therapies. The company targets severe unmet medical needs in inherited retinal diseases and other indications, and operates its own commercial-scale manufacturing facilities in London and Shannon, Ireland to support global regulatory filings and potential product launches.
Average Trading Volume: 497,099
Technical Sentiment Signal: Buy
Current Market Cap: $916.3M
Find detailed analytics on MGTX stock on TipRanks’ Stock Analysis page.